AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02019797 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desflurane
Description: Patients are assigned to desflurane group (Des) or propofol group (Prop). Des receives desflurane (1-2 MAC) inhalation between the induction of anesthesia and before cardiopulmonary bypass (CPB). After the induction of CPB, the anesthesia in Des is switched to a total intravenous anesthesia (TIVA) with propofol. Prop receives a propofol during the surgery.
Study NCT02591225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatranetexilate
Description: After inclusion of the subjects with LA thrombus, they are treated according to the randomization either with Dabigatran (150 mg bid) or Phenprocoumon (INR adjusted once) for the treatment period of 12 months.
Study NCT02591225 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenprocoumon
Description: After inclusion of the subjects with LA thrombus, they are treated according to the randomization either with Dabigatran (150 mg bid) or Phenprocoumon (INR adjusted once) for the treatment period of 12 months.
Study NCT03298659 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: iFR
Description: Treatment guided by instantaneous wave-free ratio
Study NCT03298659 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: CMR
Description: Treatment guided by stress perfusion CMR
Study NCT04618848 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Fingerstick blood draw
Description: Each participant shall be pricked twice in order to perform CBC test
Study NCT04286048 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weight implement
Description: The technique will be done by making the same movement of the launch, but with the weight implement. The physiotherapist will be next to the pitcher, noting that there is no pain or discomfort when launching. The session will be held for 15min with 30 seconds of rest between each launch, until reaching 15 pitches.~The sessions will be directed by a physiotherapist, in charge of supervising that the pitcher is correctly making the requested movement.
Study NCT04074408 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: stereotactic surgery
Description: stereotactic aspiration surgery
Study NCT04074408 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hUMSCs
Description: single intracavitary infusion 1 day after stereotactic aspiration surgery
Study NCT04074408 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: placebo
Description: single intracavitary infusion 1 day after stereotactic aspiration surgery
Study NCT03573271 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MCD
Description: Micro-coring skin removal with automated coring device
Study NCT00793013 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Volume-Cycled Assist-Control (AC) mode
Description: 1. Patients ventilated with volume-cycled assist-control mode with PEEP and goal FIO2 \< 40%~2. Rate of mandatory time-cycled, pressure controlled breaths,initially at 12 per breaths/min~3. Initial tidal volume set at 8mL/kg using predicted body weight (PBW) with a goal of 6mL/kg \& setting positive end-expiratory pressure (PEEP) based on level of initial FiO2~4. Inspiratory to Expiratory ratio set at 1:1 to 1:3~5. If frequency of triggered breaths increased greater than 10 per min sedation will be increased. If needed,rate of mandatory breaths increased~6. Mgmt of PEEP will be conducted as per the ARDSnet Protocol~7. Oxygenation goal PaO2: PaO2-55-80 mm Hg O2 Sat: 88-95%~8. Tidal volume and respiratory rate adjusted to the desired pH and plateau pressures per ARDSnet protocol
Study NCT00793013 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Airway Pressure Release Ventilation (APRV) mode
Description: 1. Ventilation uses Drager Model X1~2. Spontaneous breathing allowed throughout ventilatory cycle at 2 airway pressure levels~3. Time periods for the high \& low pressure levels can be set independently~4. Duration of the lower pressure level will be adjusted to allow expiratory flow to decay to 75% of total volume~5. Duration of higher pressure levels will be adjusted to produce 12 pressure shifts per min~6. Spontaneous frequency will be targeted for 6 to 18 breaths/per min~7. If spontaneous breathing is achieved,level of sedation will be decreased~8. If spontaneous respirations are >20 breaths/min, sedation will be increased~9. If spontaneous breathing frequency increased greater than 20/per min, sedation was increased and if needed the mechanical frequency increased
Study NCT02726854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Patients with pancreatic cancer who are failed of receiving first-line chemotherapy and cannot tolerate second-line chemotherapy or unwilling to receive second-line chemotherapy will receive Apatinib Tablets (850mg once daily, orally) 30 minutes after meal with warm water. Take 28 days as a cycle, patients will receive this treatment until they have got disease progressed.
Study NCT05006001 — intervention group
Intervention type: DRUG
Intervention: Colchicine and NSAID
Description: Colchicine and nonsteroidal anti-inflammatory drug combination therapy
Study NCT02879188 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: Patients will initiate inpatient physical therapy on the day of their surgery including attempted ambulation with an assistive device that is supervised by a physical therapist.
Study NCT02879188 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standing
Description: Patients will initiate inpatient physical therapy on postoperative day 1. On the day of their surgery they will dangle their feet over the edge of the bed with supervision of nursing.
Study NCT00687427 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaires and motor/sensitivity testing
Description: Group A:~1. Full assessment (using the various measures described) will be carried out 0-3 weeks since referral.~2. Treatment will focus on the patient's needs and in accordance with the physicians requests.~3. Three months post initial treatment re-assessment will be conducted.
Study NCT00687427 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaires and motor/sensitivity testing
Description: Group B Researcher will contact by phone previous patients that were treated in the occupational therapy department in the past half year and a year, in order to get their permission to participate (retrospectively) in this research. After getting their consent, a questionnaire concerning their RTW will be posted to the subjects.
Study NCT00687427 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaires and motor/sensitivity testing
Description: Group C Researcher will contact by phone previous patients that were treated in the occupational therapy department in the past half year and a year, in order to get their permission to participate (retrospectively) in this research. After getting their consent, a questionnaire concerning their RTW will be posted to the subjects.
Study NCT01262820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Pazopanib, 800 mg by mouth daily each 21 day cycle
Study NCT01575626 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: All active comparators of this study have the same intervention as mentioned ahead:~First IOP measurement will be performed just before anesthesia induction. Standard general anesthesia will be induced using propofol (5 mcg/ml) administered by target controlled infusion (TCI - Schnider model),fentanyl and rocuronium according to standard protocol of general anesthesia. The second IOP measurement will be performed just before tracheal intubation.~Following tracheal intubation, concentration of propofol will be decreased till 0 and anesthesia with sevoflurane will be started, followed by 3 more IOP measurements for different end-tidal sevoflurane concentrations (Consented patients will be randomly allocated to one of three groups as mentioned).~Total of 5 IOP measurements. IOP will be measured by the ophthalmologist via both TonoPen XL and Schioz devices.
Study NCT00104520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZLI 75 mg two times a day (BID)/three times a day (TID)
Study NCT00104520 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo two times a day (BID)/three times a day (TID)
Study NCT00004101 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: apolizumab
Study NCT03714581 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microablative Fractional CO2 Laser Therapy
Description: 5 laser therapies intravaginally administered will be applied at monthly intervals.
Study NCT03714581 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Microablative Fractional CO2 Laser Therapy
Description: 5 laser therapies intravaginally administered will be applied at monthly intervals.
Study NCT00752804 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dialysis during 4 hours
Description: Blood and dialysate sampling
Study NCT00752804 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dialysis during 6 hours
Description: Blood and dialysate sampling
Study NCT00752804 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dialysis during 8 hours
Description: Blood and dialysate sampling
Study NCT04454853 — intervention group
Intervention type: OTHER
Intervention: Lung cancer
Description: Paraneoplastic neurological syndrome (PNS) is a clinical syndrome that affects the central nervous system, peripheral nerves, neuromuscular junctions and muscles by the distant influence of the tumor. No tumor cells are visible at the neuropathy site.
Study NCT04454853 — intervention group
Intervention type: OTHER
Intervention: Suspected lung cancer
Description: Paraneoplastic neurological syndrome (PNS) is a clinical syndrome that affects the central nervous system, peripheral nerves, neuromuscular junctions and muscles by the distant influence of the tumor. No tumor cells are visible at the neuropathy site.
Study NCT04454853 — intervention group
Intervention type: OTHER
Intervention: Positive methylated DNA
Description: Tumor-free DNA (cfDNA) methylation detection is to determine the cancer condition and cancer type of the subject by detecting the methylation of free DNA released by tumor cells.
Study NCT03111641 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Lung ultrasonography
Description: Lung ultrasound scan during preoperative anaesthesia consultation
Study NCT02967783 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ID adaptor
Description: ID adaptor fixed to the end of a standard ID needle and syringe to facilitate ID administration of the inactivated poliovirus vaccine
Study NCT02967783 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ID Jet Injector (Tropis, Pharmajet)
Description: ID disposable syringe (needle free) jet injector to facilitate ID administration of the inactivated poliovirus vaccine
Study NCT02967783 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Needle and syringe
Description: Standard ID needle and syringe for ID administration of the inactivated poliovirus vaccine
Study NCT00982423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: Subjects received their clinically prescribed dose of furosemide for a 3 week stabilization period, then were assessed for cardiorenal and humoral function. Subjects then had a 50% reduction of the furosemide dose for a 3 week stabilization period, and were assessed for cardiorenal and humoral function again.
Study NCT01600170 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin (generic Lipitor)
Description: Atorvastatin is an FDA approved prescription drug which is frequently used to lower cholesterol levels.It is available in the form of tablets ranging in dose from 10-80mg.
Study NCT01600170 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: A substance containing no medication and prescribed or given to reinforce a patient's expectation to get well.
Study NCT01114399 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Diet and Vascular Health
Description: One group will consume 400g of standard broccoli each week for 12weeks; the second group will consume 400g of the high glucosinolate broccoli each week for 12weeks while the third group will consume 400g of peas each week for 12weeks. The broccoli and the peas will be consumed on top of the volunteer's standard diet.
Study NCT01114399 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Diet and Vascular Health Study
Description: One group will consume 400g of standard broccoli each week for 12weeks; the second group will consume 400g of the high glucosinolate broccoli each week for 12weeks while the third group will consume 400g of peas each week for 12weeks. The broccoli and the peas will be consumed on top of the volunteer's standard diet.
Study NCT00568386 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systane Lubricant Eye Drops
Description: Systane Lubricant Eye Drops 1 drop each eye once time
Study NCT00568386 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Optive Lubricant Eye Drops
Description: Optive Lubricant Eye Drops 1 drop each eye one time
Study NCT02465424 — intervention group
Intervention type: OTHER
Intervention: quality of life questionnaires
Description: Randomised allocation of 4 validated quality of life questionnaires followed by study specific overview questionnaire
Study NCT01798849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8892
Study NCT01798849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for MK-8892
Study NCT02163941 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compassion Training
Study NCT02550405 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Craving behavioral intervention
Description: The CBI was given once a week for 6 weeks, conducted by four therapists. A pair of therapists was randomly assigned to a CBI+ group. Each session included 5 parts in 2.5-3 hours: warming-up exercise, discussion about the homework from the last session, main structured activity, brief summary, and the homework assignment. There were 6 sessions with each focused on a topic: recognize craving and its relationship with IGD; reduce craving through ameliorating the salience of cues and irrational beliefs, withdrawal symptoms and other negative affects; enhance self-monitoring and control for craving through time management training; relieve fulﬁllment of psychological needs through Internet use and attenuate the relation between craving and gaming behaviors through coping skill training
Study NCT03282214 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-management energy conservation
Description: The experimental group will receive four sessions approximately every three weeks with the PI. These sessions will correspond to the cycles of chemotherapy they will receive, with the first two sessions being during cycle 1, and sessions 3 and 4 being during cycles 2 and 3 of chemotherapy, respectively. The women will be instructed on how to assess their activity patterns by making a list prioritizing their usual activities. The journal and priority list (a to do list) provide the basis for the second session. In this session, the participant will learn to create a plan for managing valued activities to minimize the amount of energy used, to report the fatigue experienced during and after an activity done in the journal and will learn strategies to manage fatigue and optimize activity. In the third session, the participant will evaluate and revise their individualized plan. In addition, the participant will be instructed to wear a pedometer to record objective physical activity.
Study NCT02413151 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training program
Description: The exercise sessions will be hospital-based, 3 times a week for 60 minutes each, on non-consecutive days for 6 months. Selected the aerobic interval training (AIT) method for the development of cardiopulmonary system and the inclusion of resistance and sensorimotores exercises. The AIT comprises 4 interval training periods (high intensity) and 3 active pauses (moderate intensity) between interval training periods. The patient will warmup for 10 minutes at 50% to 60% of HRpeak from CPET, before walking to four 4 minutes intervals at 90 to 95% of peak HR. Each interval, including the last one, is separate by 3 minutes active pauses, walking at 60% to 70% of HRpeak. Total aerobic exercise time at this moment will be 28 minutes and will be maintain to the end of ExT intervention period.
Study NCT02413151 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac resynchronization therapy (CRT)
Description: Implantation will be performed according to standard techniques of biventricular pacing. The CRT includes a generator and three leads, used to correct ventricular dyssynchrony.
Study NCT02413151 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Description: Implantation will be performed according to standard techniques of biventricular pacing. The CRT includes a generator and three leads, used to correct ventricular dyssynchrony.
Study NCT00002618 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: filgrastim
Study NCT00002618 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cytarabine
Study NCT00002618 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin hydrochloride
Study NCT00002618 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leucovorin calcium
Study NCT00002618 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mercaptopurine
Study NCT00002618 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Study NCT00002618 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Study NCT00002618 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vincristine sulfate
Study NCT00002618 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: low-LET cobalt-60 gamma ray therapy
Study NCT00002618 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: low-LET electron therapy
Study NCT00002618 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: low-LET photon therapy
Study NCT02165098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine prolonged release tablet A
Description: Cariprazine prolonged release tablet A - fasted
Study NCT02165098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine prolonged release tablet B
Description: Cariprazine prolonged release tablet B - fasted
Study NCT02165098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine capsule
Description: Cariprazine capsule - fasted
Study NCT02165098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine PR tablet A
Description: Cariprazine Prolonged Release tablet A - fed
Study NCT02165098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine PR tablet B
Description: Cariprazine Prolonged Release tablet B - fed
Study NCT02442804 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: POMx
Description: Pomegranate supplement (1g) by mouth twice per day for 7 days
Study NCT02442804 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (for POMx, containing no antioxidant contents; 1g) capsule by mouth twice per day for 7 days
Study NCT01319552 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Fresh transfusion
Description: 1 unit autologous transfusion of red blood cells stored for 3-7 days under standard conditions
Study NCT01319552 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fresh transfusion
Description: 1 unit autologous transfusion of red blood cells stored for 3-7 days under standard conditions
Study NCT01319552 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Old transfusion
Description: 1 unit autologous transfusion of red blood cells stored for 40-42 days under standard conditions
Study NCT01319552 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Old transfusion
Description: 1 unit autologous transfusion of red blood cells stored for 40-42 days under standard conditions
Study NCT03200886 — intervention group
Intervention type: DEVICE
Intervention: Sinovial H-L
Description: Patients were treated with an hybrid form of hyaluronic acid (Sinovial H-L) obtained through thermo-chemical processes from the combination of high (1100-1400 kDa) and low (80-100 kDa) MW fractions.
Study NCT03200886 — intervention group
Intervention type: DRUG
Intervention: Triamcinolone Acetonide
Description: The patients have received two i.a. injections (at baseline and 15 days apart) of 0.5 ml of triamcinolone acetonide (Kenacort® 20 mg, Bristol-Myers Squibb Srl)
Study NCT00892216 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupressure (BioBand)
Description: Band will remain on from 20 minutes before surgery until the end of the hospital stay.
Study NCT00892216 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Acupressure (BioBand)
Description: Band will remain on from 20 minutes before surgery until the end of the hospital stay. The same band will be placed and turned so the beads face the corresponding point on the dorsal surface of the upper limb area.
Study NCT00900952 — intervention group
Intervention type: OTHER
Intervention: Clinical record review
Study NCT02543060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: stannous fluoride toothpaste
Description: 0.454% stannous fluoride toothpaste
Study NCT02543060 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: cavity protection toothpaste
Description: 0.243% sodium fluoride toothpaste
Study NCT01122121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprorelin SR
Description: Leuprorelin SR injection